

Now being on warfarin can take up less of your time



Encourage your patients to **say yes** to the freedom and efficiency of warfarin management with **patient self-testing**



Better use of everyone's time

Monitoring your warfarin patients' PT/INR is essential for effective anticoagulation management. It enables necessary dose adjustments to be made to help increase their time in therapeutic range, but for many patients this can mean a lot of visits to the clinic or hospital.

Self-testing with the CoaguChek[®] INRange system allows patients to measure their PT/INR themselves, anytime they like. Compared to usual care, where patients need to visit the clinic or hospital for a venous blood sample which is then sent to a laboratory for analysis, this gives patients more freedom and more time to themselves.¹²



Patients who self-test can share their PT/INR results on a regular basis, enabling you to closely monitor their PT/INR and make necessary dose adjustments without waiting for laboratory results.^{3,4}





Patient self-testing (PST) gives you faster results for immediate treatment decisions, allowing for a more streamlined approach to monitoring, compared to usual care routines with venipuncture and laboratory INR testing.⁵⁻⁹

This could mean more workflow efficiency and less overcrowding at your clinic.^{6,10} Also, the more your patients self-test at home, the more time you can dedicate to other important work.



Improved patient engagement

In addition to saving time, self-testing can also motivate patients to become more involved in their own care.^{11,12} In a study of 2,922 warfarin patients, 87% of those randomized to self-testing adhered to their prescribed testing frequency compared with 52% of those who attended clinic appointments for testing.¹³

The CoaguChek[®] INRange system provides accurate PT/INR results in less than a minute and can be used by patients of all ages.^{3,11,13–16} With a short training session, your patients can learn to test themselves with ease and confidence. In fact, studies have shown that approximately three quarters of suitable patients can be taught how to correctly measure their own PT/INR values.^{14,15}







Optimized warfarin management

With PST, any necessary adjustments to your patients' warfarin dosage can be made sooner than if they had to visit the clinic for testing. This can give them more time in therapeutic range and provide a more efficient means of warfarin monitoring and management.^{3,4,17}

Patients who monitor their own PT/INR spend more time in therapeutic range compared with VKA patients who are tested in the laboratory or clinic. This can decrease the risk of adverse events for patients who self-test.^{3,4,17-19}



PST not only gives patients more time to enjoy their day-to-day life, it can also help them gain better control of their medication.^{34,17} This may lead to better health outcomes, treatment satisfaction and improved quality of life.^{3,4,13,17-22}







Ideal candidates for patient self-testing would be patients who are: 2,12,23-25



Patients with a history of stroke, poor cognition, low literacy, or poor manual dexterity are unsuitable for self-testing.²⁴

Learn more about the benefits of patient self-testing for you and your patients at *coaguchek.ca* and say yes to patient self-testing.



References

- Nagler, M., Raddatz-Müller, P., Schmid, P., Bachmann, L.M., Wuillemin, W.A. (2013). Accuracy of the point-of-care coagulometer CoaguChek XS in the hands of patients. *J Thromb Haemost* 11, 197–199.
- 2 National Institute for Health and Care Excellence. (2014). Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system and the INRatio2 PT/INR monitor). *NICE diagnostics guidance DG14*. Available at http://www.nice.org.uk/guidance/DG14 Last accessed August 2016.
- 3 Sharma, P. Sootland, G., Cruickshank, M., Tassie, E., Fraser, C., Burton, C. et al. (2015). The clinical effectiveness and cost-effectiveness of point-of-care tests (CoaguChek system, INRatio2 PT/INR monitor and ProTime Microcoagulation system) for the self-monitoring of the coagulation status of people receiving long-term vitamin K antagonist therapy, compared with standard UK practice: systematic review and economic evaluation. *Health Technol Assess* 19, 1–172.
- 4 Bloomfield, H.E., Krause, A., Greer, N., Taylor, B.C., MacDonald, R., Rutks, I. et al. (2011). Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. *Ann Intern Med* 154, 472–482.
- Wurster, M., Doran, T. (2006). Anticoagulation management: a new approach. *Dis Manag* 9, 201–209.
- 6 Larsson, A., Greig-Pylypczuk, R., Huisman, A. (2015). The state of pointof-care testing: a European perspective. Ups J Med Sci 120, 1–10.
- 7 Ryan, F., O'Shea, S., Byrne, S. (2010). The 'carry-over' effects of patient self-testing: positive effects on usual care management by an anticoagulation management service. *Thromb Res* 126, e345-e348.
- 8 Gubala, V., Harris, L.F., Ricco, A.J., Tan, M.X., Williams, D.E. (2012). Point of care diagnostics: status and future. *Anal Chem* 84, 487–515.
- 9 Bereznicki, L.R.E., Jackson, S.L., Peterson, G.M. (2013). Supervised patient self-testing of warfarin therapy using an online system. *J Med Internet Res* 15, e138.
- 10 Huston, T. (2009). POC PT/INR testing: a better choice for patients and providers. *Med Lab Obs* 41, 28–30.
- 11 Gardiner, C., Williams, K., Mackie, I.J., Machin, S.J., Cohen, H. (2005). Patient self-testing is a reliable and acceptable alternative to laboratory INR monitoring. *Br J Haematol* 128, 242–247.
- 12 Burgwinkle, P., Dice, G., Ezekowitz, M.D., Fintel, D.J., Franke, C., Frazier, T. (2008). Oral anticoagulation patient self-testing: consensus guidelines for practical implementation. *Managed Care* 17 (Supplement 9), 1–8.
- 13 Matchar, D.B., Jacobson, A., Dolor, R., Edson, R., Uyeda, L., Phibbs, C.S. et al. (2010). Effect of home testing of international normalized ratio on clinical events. *N Engl J Med* 363, 1608–1620.
- 14 Connock, M., Stevens, C., Fry-Smith, A., Jowett, S., Fitzmaurice, D., Moore, D. et al. (2007). Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. *Health Technol Assess* 11, (38) iii-vi ix-66.

- 15 Dolor, R.J., Ruybalid, R.L., Uyeda, L., Edson, R.G., Phibbs, C., Vertrees, J.E. et al. (2010). An evaluation of patient self-testing competency of prothrombin time for managing anticoagulation: pre-randomization results of VA Cooperative Study #481--The Home INR Study (THINRS). J Thromb Thrombolysis 30, 263–275.
- 16 Heneghan, C., Ward, A., Perera, R., Self-Monitoring Trialist Collaboration, Bankhead, C., Fuller, A. et al. (2012). Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. *Lancet* 379, 322–334.
- 17 Heneghan, C.J., Garcia-Alamino, J.M., Spencer, E.A., Ward, A.M., Perera, R., Bankhead, C. et al. (2016). Self-monitoring and selfmanagement of oral anticoagulation. *Cochrane Database Syst Rev* 7, CD003839.
- 18 Khan, T.I., Kamali, F., Kesteven, P., Avery, P., Wynne, H. (2004). The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. *Br J Haematol* 126, 557–564.
- 19 Heneghan, C., Alonso-Coello, P., Garcia-Alamino, J.M., Perera, R., Meats, E., Glasziou, P. (2006). Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. *Lancet* 367, 404–411.
- 20 Bussey, H.I., Bussey, M., Bussey-Smith, K.L., Frei, C.R. (2013). Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study. *Pharmacotherapy* 33, 1136–1146.
- 21 Meyer, S., Frei, C.R., Daniels, K.R., Forcade, N.A., Bussey, M., Bussey-Smith, K.L. et al. (2013). Impact of a new method of warfarin management on patient satisfaction, time, and cost. *Pharmacotherapy* 33, 1147–1155.
- 22 Salvador, C.H., Ruiz-Sanchez, A., González de Mingo, M.A., Carmona Rodríguez, M., Carrasco, M.P., Sagredo, RG. et al. (2008). Evaluation of a telemedicine-based service for the follow-up and monitoring of patients treated with oral anticoagulant therapy. IEEE Trans Inf *Technol Biomed* 12, 696–706.
- 23 Holbrook, A., Schulman, S., Witt, D.M., Vandvik, PO., Fish, J., Kovacs, M.J. et al. (2012). Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 141, e152S-e184S.
- 24 Jennings, I., Kitchen, D., Keeling, D., Fitzmaurice, D., Heneghan, C., BCSH Committee. (2014). Patient self-testing and self-management of oral anticoagulation with vitamin K antagonists: guidance from the British Committee for Standards in Haematology. *Br J Haematol* 167, 600–607.
- 25 Ansell, J., Jacobson, A., Levy, J., Völler, H., Hasenkam, J.M., International Self-Monitoring Association for Oral Anticoagulation (2005). Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation. *Int J Cardiol* 99, 37–45.





COAGUCHEK is a trademark of Roche. © Roche 2019. www.coaguchek.ca

